In a cohort of pediatric patients with acute lymphoblastic leukemia receiving treatment with vincristine (66), however, we found that common OATP1B3 variants were not statistically significantly associated with VIPN (Supplemental Table 5), suggesting that genetic approaches may be less suitable for the optimization of preventative treatment strategies in this context. Here, SLCO1B3 is linked to acute lymphoblastic leukemia.